Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 48.61%.

  • Viridian Therapeutics, Inc.\DE's EBITDA Margin rose 874095300.0% to 48.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 427.38%, marking a year-over-year increase of 843699700.0%. This contributed to the annual value of 89502.32% for FY2024, which is 140227000.0% down from last year.
  • Viridian Therapeutics, Inc.\DE's EBITDA Margin amounted to 48.61% in Q3 2025, which was up 874095300.0% from 134548.0% recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's EBITDA Margin peaked at 48.61% during Q3 2025, and registered a low of 134548.0% during Q2 2025.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's EBITDA Margin had a median value of 66043.06% in 2023 and averaged 53162.47%.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's EBITDA Margin tumbled by -648996100bps in 2023 and then surged by 874095300bps in 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's EBITDA Margin (Quarter) stood at 13598.13% in 2021, then crashed by -217bps to 43080.95% in 2022, then tumbled by -114bps to 92302.78% in 2023, then fell by -21bps to 112037.5% in 2024, then skyrocketed by 100bps to 48.61% in 2025.
  • Its EBITDA Margin was 48.61% in Q3 2025, compared to 134548.0% in Q2 2025 and 120356.94% in Q1 2025.